BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 29091892)

  • 1. Nitric oxide bioavailability dysfunction involves in atherosclerosis.
    Chen JY; Ye ZX; Wang XF; Chang J; Yang MW; Zhong HH; Hong FF; Yang SL
    Biomed Pharmacother; 2018 Jan; 97():423-428. PubMed ID: 29091892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelium-Derived Nitric Oxide as an Antiatherogenic Mechanism: Implications for Therapy.
    Sukhovershin RA; Yepuri G; Ghebremariam YT
    Methodist Debakey Cardiovasc J; 2015; 11(3):166-71. PubMed ID: 26634024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homocysteine-Induced Endothelial Dysfunction.
    Lai WK; Kan MY
    Ann Nutr Metab; 2015; 67(1):1-12. PubMed ID: 26201664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired flow-mediated dilation with age is not explained by L-arginine bioavailability or endothelial asymmetric dimethylarginine protein expression.
    Gates PE; Boucher ML; Silver AE; Monahan KD; Seals DR
    J Appl Physiol (1985); 2007 Jan; 102(1):63-71. PubMed ID: 16946027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pivotal role of nitric oxide for vascular health.
    Cooke JP
    Can J Cardiol; 2004 Aug; 20 Suppl B():7B-15B. PubMed ID: 15309199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-Arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor.
    Böger RH; Ron ES
    Altern Med Rev; 2005 Mar; 10(1):14-23. PubMed ID: 15771559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles of oxidants, nitric oxide, and asymmetric dimethylarginine in endothelial function.
    Siekmeier R; Grammer T; März W
    J Cardiovasc Pharmacol Ther; 2008 Dec; 13(4):279-97. PubMed ID: 18945874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis.
    Antoniades C; Shirodaria C; Leeson P; Antonopoulos A; Warrick N; Van-Assche T; Cunnington C; Tousoulis D; Pillai R; Ratnatunga C; Stefanadis C; Channon KM
    Eur Heart J; 2009 May; 30(9):1142-50. PubMed ID: 19297385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome?
    Chan NN; Chan JC
    Diabetologia; 2002 Dec; 45(12):1609-16. PubMed ID: 12488950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ADMA and hyperhomocysteinemia.
    Dayal S; Lentz SR
    Vasc Med; 2005 Jul; 10 Suppl 1():S27-33. PubMed ID: 16444866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arginase as a potential target in the treatment of cardiovascular disease: reversal of arginine steal?
    Pernow J; Jung C
    Cardiovasc Res; 2013 Jun; 98(3):334-43. PubMed ID: 23417041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nitric oxide dynamics and endothelial dysfunction in type II model of genetic diabetes.
    Bitar MS; Wahid S; Mustafa S; Al-Saleh E; Dhaunsi GS; Al-Mulla F
    Eur J Pharmacol; 2005 Mar; 511(1):53-64. PubMed ID: 15777779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roles of Vascular Oxidative Stress and Nitric Oxide in the Pathogenesis of Atherosclerosis.
    Förstermann U; Xia N; Li H
    Circ Res; 2017 Feb; 120(4):713-735. PubMed ID: 28209797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelial dysfunction in morbid obesity.
    Mauricio MD; Aldasoro M; Ortega J; Vila JM
    Curr Pharm Des; 2013; 19(32):5718-29. PubMed ID: 23448493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelial function and oxidative stress in cardiovascular diseases.
    Higashi Y; Noma K; Yoshizumi M; Kihara Y
    Circ J; 2009 Mar; 73(3):411-8. PubMed ID: 19194043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA.
    Sydow K; Mondon CE; Cooke JP
    Vasc Med; 2005 Jul; 10 Suppl 1():S35-43. PubMed ID: 16444867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitrergic system and plasmatic methylarginines: Evidence of their role in the perinatal programming of cardiovascular diseases.
    Bassareo PP; Mussap M; Bassareo V; Flore G; Mercuro G
    Clin Chim Acta; 2015 Dec; 451(Pt A):21-7. PubMed ID: 26004093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidative stress and endothelial dysfunction: say NO to cigarette smoking!
    Grassi D; Desideri G; Ferri L; Aggio A; Tiberti S; Ferri C
    Curr Pharm Des; 2010; 16(23):2539-50. PubMed ID: 20550504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Asymmetric dimethylarginine--a novel cardiovascular risk factor].
    Siroká R; Cibulka R; Rajdl D; Racek J
    Vnitr Lek; 2006 Mar; 52(3):249-55. PubMed ID: 16722156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-arginine, tetrahydrobiopterin, nitric oxide and diabetes.
    Hoang HH; Padgham SV; Meininger CJ
    Curr Opin Clin Nutr Metab Care; 2013 Jan; 16(1):76-82. PubMed ID: 23164986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.